Katharine Spink, Ph.D. became Asterias Biotherapeutics Chief Operating Officer in April 2013. Dr. Spink previously served as Senior Vice President of Alliance Management and Cell Therapy Program Operations at Geron Corporation, where she was employed in roles of increasing responsibility within R&D and business development from 2003 through 2011. Prior to joining Geron, Dr. Spink was a management consultant at McKinsey & Company, advising clients in the biotechnology, pharmaceutical, and medical device industries on matters relating to R&D strategy, business development, and marketing. Dr. Spink graduated Magna Cum Laude and Phi Beta Kappa with a B.A. in Biochemistry from Rice University, and received her Ph.D. in Cancer Biology from Stanford University.